For research use only. Not for therapeutic Use.
AVJ16 is a cancer cell migration inhibitor that targets the insulin-like growth factor 2 mRNA binding protein IGF2BP1 to inhibit the migration of H1299 cells with high endogenous IGF2BP1 expression. AVJ16 interferes with IGF2BP1 binding target mRNA to regulate gene expression and translation[1].
| Catalog Number | I044034 |
| CAS Number | 2775241-92-2 |
| Synonyms | [4-(1,3-benzodioxol-5-yl)piperazin-1-yl]-[4-[[2-(hydroxymethyl)indol-1-yl]methyl]phenyl]methanone |
| Molecular Formula | C28H27N3O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C28H27N3O4/c32-18-24-15-22-3-1-2-4-25(22)31(24)17-20-5-7-21(8-6-20)28(33)30-13-11-29(12-14-30)23-9-10-26-27(16-23)35-19-34-26/h1-10,15-16,32H,11-14,17-19H2 |
| InChIKey | SBMDRXUGWAAAMV-UHFFFAOYSA-N |
| SMILES | C1CN(CCN1C2=CC3=C(C=C2)OCO3)C(=O)C4=CC=C(C=C4)CN5C6=CC=CC=C6C=C5CO |
| Reference | [1]. Singh A, et al. Development of a Novel IGF2BP1 Inhibitor as Metastasis-Specific Therapeutic Agent[J]. European Journal of Cancer, 2022, 174: S104-S105. |
